VGI Health Technology Limited

NSX:VTL ISIN:AU0000152597

Azure Health Technology LimitedVGI Health Technology Limited (NSX:VTL) is an Australian public listed biotechnology company developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

  

News

VGI Health Technology Limited (NSX:VTL) Contract with Resonance Health (ASX:RHT)

🕔1/25/2022 8:42:00 AM 1004

Invictus Ops Pty Ltd, a wholly owned subsidiary of NSX-listed VGI Health Technology Limited (NSX:VTL), is pleased to announce that it has contracted Resonance Health Ltd (ASX:RHT) to provide liver-fat quantification services for its clinical study on a potential new treatment for Non-Alcoholic Steatohepatitis.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Nutraceutical Products Listed on Amazon

🕔1/20/2022 9:05:00 AM 938

Invictus Nutraceuticals, Inc. (Florida, USA), a wholly owned subsidiary of VGI Health Technology Limited (NSX:VTL), is pleased to announce that both NE1-Elite(R) and NE1-Heart(R) are now available for sale on Amazon in the United States.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Quarterly update

🕔1/19/2022 10:08:00 AM 1003

The Directors of VGI Health Technology Limited (NSX:VTL) are pleased to provide the following update for the quarter ending 31 December 2021.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Patent application lodged

🕔12/7/2021 9:14:00 AM 3082

VGI Health Technology Limited (NSX:VTL), is pleased to announce that its wholly-owned subsidiary, Invictus Biotechnology Pty Ltd, has lodged a new PCT Patent Application titled: 'Transmucosal delivery of tocotrienols' (PCT patent application number: PCT/AU2021/051449).

Read Full Article

VGI Health Technology Limited (NSX:VTL) partners with ENDRA Life Sciences in NAFLD/NASH Phase II Clinical Study

🕔11/29/2021 8:15:00 AM 2277

In September 2015, a Phase Ia clinical study on IVB001 had positive topline data where all primary endpoints were achieved, including: confirmation of the bioavailability of the compound, with good plasma levels, dose relationship and duration of plasma levels achieved.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Japanese Patent to be Granted

🕔10/18/2021 11:58:00 AM 3367

VGI Health Technology Limited (NSX:VTL) is pleased to announce that the Japanese Patent Office intends to grant a patent for the Transmucosal Delivery of Tocotrienols.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Quarterly Update

🕔10/8/2021 8:53:00 AM 2235

The Directors of VGI Health Technology Limited (NSX:VTL) are pleased to provide the following update for the quarter ending 30 September 2021.

Read Full Article

VGI Health Technology Limited (NSX:VTL) HREC Approval from RMH

🕔10/6/2021 9:33:00 AM 2269

VGI Health Technology Limited (NSX:VTL) is pleased to announce that its wholly owned subsidiary, Invictus Ops Pty Ltd, has received Human Research Ethics Committee (HREC) approval from The Royal Melbourne Hospital.

Read Full Article

VGI Health Technology Limited (NSX:VTL) Draw Down of Convertible Note Facility

🕔10/5/2021 4:06:00 PM 1969

VGI Health Technology Limited (NSX:VTL) is pleased to announce that it has agreed revised terms with cornerstone investor Mr Aiden Jiang for the draw down of $1,500,000 from a previously agreed convertible loan facility.

Read Full Article

VGI Health Technology Limited (NSX:VTL) FY21 Annual Report issued to Shareholders

🕔9/22/2021 10:36:00 AM 2046

VGI Health Technology Limited (NSX:VTL) is pleased to present the FY21 Annual Report to Shareholders.

Read Full Article
###

15,590 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 1089) (Last 30 Days: 4321) (Since Published: 15590) 

Company Data

    Headquarters
  • Level 45, Suite 03
    19-29 Martin Place
    Sydney, NSW, 2003
    Australia
  • Telephone
  • +61-2-8279-8908 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.vgiht.com

Company Reports

Quarterly Report

Social Media